Imatinib

small molecule

Identifier: CI-DRUG-00000295
Entity page: /drug/imatinib ↗
Edges: 523

Neighbours: 24 cancers4 genes11 variants10 trials15 approvals
Drawn: 60 of 64 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Imatinib approved for …APPROVED_FOR30 of 55show all (up to 200)
→ approved for	Malignant Gastrointestinal Stromal Tumorsubtype 2 source records aggregated	supports	FDA ORIG	Malignant Gastrointestinal Stromal Tumor	2	Regulatory	openfda	graph →
→ approved for

→ approved for

EMA · EU · 2021Imatinib Koanaa is indicated for the treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy. adult patients with relapsed or refractory Ph+ ALL as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR? rearrangement. The effect of Imatinib on the outcome of bone marrow transplantation has not been determined. Imatinib Koanaa is indicated for the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery. In adult and paediatric patients, the effectiveness of Imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with unresectable and/or metastatic GIST and DFSP and on recurrence-free survival in adjuvant GIST. The experience with Imatinib in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1). Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases.

EMA (EU) · withdrawn · 2021-09-22 · Imatinib Koanaa is indicated for the treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) posi…

—

withdrawn

not mapped

Regulatory

ema

open ↗

→ approved for

EMA · EU · 2017Imatinib Teva B.V. is indicated for the treatment of: Paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment. Paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. Adult patients with Ph+ CML in blast crisis. Adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy. Adult patients with relapsed or refractory Ph+ ALL as monotherapy.  Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. Adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR? rearrangement. The effect of imatinib on the outcome of bone marrow transplantation has not been determined. Imatinib Teva B.V. is indicated for: The treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST). The adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment. The treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery. In adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with unresectable and/or metastatic GIST and DFSP and on recurrence-free survival in adjuvant GIST. The experience with imatinib in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited. There are no controlled trials demonstrating a clinical benefit or increased survival for these diseases.

EMA (EU) · withdrawn · 2017-11-15 · Imatinib Teva B.V. is indicated for the treatment of: Paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (…

—

withdrawn

not mapped

Regulatory

ema

open ↗

Imatinib predicts response to …PREDICTS_RESPONSE_TO15 of 120show all (up to 200)
← predicts response to	ABL1 Fusionfusion 3 source records aggregated	sensitivity	A	Acute Myeloid Leukemia,Chronic Myeloid Leukemia, BCR-ABL1 Positive	3	Curated	civic	graph →
← predicts response to	PDGFRA Fusionfusion	sensitivity	A	Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions	1	Curated	civic	graph →
← predicts response to	PDGFRB Fusionfusion	sensitivity	A	Myeloproliferative Neoplasm	1	Curated	civic	graph →
← predicts response to	KIT Exon 9 Mutation	sensitivity	A	Gastrointestinal Stromal Tumor	1	Curated	civic	graph →
← predicts response to	KIT Exon 11 Mutation	sensitivity	A	Gastrointestinal Stromal Tumor	1	Curated	civic	graph →
← predicts response to	PDGFRA D842VSNV 3 source records aggregated	resistance	B	Gastrointestinal Stromal Tumor	3	Curated	civic	graph →
← predicts response to	KIT Exon 11 Mutation 2 source records aggregated	sensitivity	B	Gastrointestinal Stromal Tumor,Melanoma	2	Curated	civic	graph →
← predicts response to	KIT EXPRESSIONexpression	sensitivity	B	Gastrointestinal Stromal Tumor	1	Curated	civic	graph →
← predicts response to	KIT Exon 9 Mutation	resistance	B	Gastrointestinal Stromal Tumor	1	Curated	civic	graph →
← predicts response to	KIT D816VSNV	resistance	B	Systemic Mastocytosis	1	Curated	civic	graph →
← predicts response to	KIT D816VSNV	sensitivity	B	Systemic Mastocytosis	1	Curated	civic	graph →
← predicts response to	KIT Exon 9 Mutation	sensitivity	B	Gastrointestinal Stromal Tumor	1	Curated	civic	graph →
← predicts response to	KIT Amplificationamplification	resistance	B	Mucosal Melanoma	1	Curated	civic	graph →
← predicts response to	KIT Mutationother	sensitivity	B	Melanoma	1	Curated	civic	graph →
← predicts response to	IKZF1 Deletiondeletion_cna	sensitivity	B	B Lymphoblastic Leukemia/Lymphoma	1	Curated	civic	graph →

Imatinib targets …TARGETS4 of 4
→ targets	KIT	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	BCR	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	ABL1	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	PDGFRB	—	INHIBITOR	—	1	Curated	chembl	graph →

Imatinib investigated for …INVESTIGATED_FOR15 of 93show all (up to 200)
→ investigated for	Gastrointestinal Stromal Tumorsubtype 2 source records aggregated	supports	A	Gastrointestinal Stromal Tumor	2	Curated	civic	graph →
→ investigated for	Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype 2 source records aggregated	supports	A	Chronic Myeloid Leukemia, BCR-ABL1 Positive	2	Curated	civic	graph →
→ investigated for	Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusionshematologic_malignancy	supports	A	Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions	1	Curated	civic	graph →
→ investigated for	Myeloproliferative Neoplasmhematologic_malignancy	supports	A	Myeloproliferative Neoplasm	1	Curated	civic	graph →
→ investigated for	Acute Myeloid Leukemiahematologic_malignancy	supports	A	Acute Myeloid Leukemia	1	Curated	civic	graph →
→ investigated for	Gastrointestinal Stromal Tumorsubtype 7 source records aggregated	supports	B	Gastrointestinal Stromal Tumor	7	Curated	civic	graph →
→ investigated for	Systemic Mastocytosishematologic_malignancy 2 source records aggregated	supports	B	Systemic Mastocytosis	2	Curated	civic	graph →
→ investigated for	Melanomacancer_family 2 source records aggregated	supports	B	Melanoma	2	Curated	civic	graph →
→ investigated for	Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype 2 source records aggregated	supports	B	Chronic Myeloid Leukemia, BCR-ABL1 Positive	2	Curated	civic	graph →
→ investigated for	Mucosal Melanomahistology	supports	B	Mucosal Melanoma	1	Curated	civic	graph →
→ investigated for	B Lymphoblastic Leukemia/Lymphomahematologic_malignancy	supports	B	B Lymphoblastic Leukemia/Lymphoma	1	Curated	civic	graph →
→ investigated for	Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusionshematologic_malignancy	supports	B	Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions	1	Curated	civic	graph →
→ investigated for	Myelodysplastic/Myeloproliferative Neoplasmhematologic_malignancy	unknown	4	Myelodysplastic/Myeloproliferative Neoplasm	1	Curated	chembl	graph →
→ investigated for	Dermatofibrosarcoma Protuberanssubtype	unknown	4	Dermatofibrosarcoma Protuberans	1	Curated	chembl	graph →
→ investigated for	Gastrointestinal Stromal Tumorsubtype	unknown	4	Gastrointestinal Stromal Tumor	1	Curated	chembl	graph →

Imatinib investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 77show all (up to 200)
→ investigated in trials for	Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype 41 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Chronic Myeloid Leukemia, BCR-ABL1 Positive	41	Observed	clinicaltrials	graph →
→ investigated in trials for	Gastrointestinal Stromal Tumorsubtype 27 trials (9 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Gastrointestinal Stromal Tumor	27	Observed	clinicaltrials	graph →
→ investigated in trials for	Leukemia 16 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Leukemia	16	Observed	clinicaltrials	graph →
→ investigated in trials for	Myeloid Leukemia 16 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Myeloid Leukemia	16	Observed	clinicaltrials	graph →
→ investigated in trials for	Acute Lymphoblastic Leukemiahematologic_malignancy 11 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Acute Lymphoblastic Leukemia	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype 8 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Melanomacancer_family 6 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Melanoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Acute Myeloid Leukemiahematologic_malignancy 4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Acute Myeloid Leukemia	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Chronic Myelomonocytic Leukemia 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Chronic Myelomonocytic Leukemia	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Hematopoietic and Lymphoid Cell Neoplasm 3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Hematopoietic and Lymphoid Cell Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Sarcoma 3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Sarcoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Acute Lymphoblastic Leukemia 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Acute Lymphoblastic Leukemia	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Chronic Eosinophilic Leukemia, Not Otherwise Specifiedhematologic_malignancy 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Chronic Eosinophilic Leukemia, Not Otherwise Specified	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Breast Neoplasm 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Breast Neoplasm	2	Observed	clinicaltrials	graph →

Imatinib studied in …STUDIED_INderived10 of 174show all (up to 200)
→ studied in	NCT06090669Phase 1 · recruiting Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency · 174 trials list this drug (36 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT06124157Phase 2 · recruiting A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) · 174 trials list this drug (36 active)	—	—	B Acute Lymphoblastic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT07585266Phase 3 · recruiting A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline) · 174 trials list this drug (36 active)	—	—	Gastrointestinal Stromal Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT05152472Phase 2 · recruiting A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments · 174 trials list this drug (36 active)	—	—	Gastrointestinal Stromal Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT05816785early Phase 1 · completed Pilot Study of Imatinib Cetuximab Combo for H & N Cancer · 174 trials list this drug (36 active)	—	—	Malignant Head and Neck Neoplasm,Head and Neck Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03722420Phase 3 · active not recruiting Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China) · 174 trials list this drug (36 active)	—	—	Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive	1	Observed	clinicaltrials	graph →
→ studied in	NCT05493215Phase 2 · recruiting Imatinib TDM in GIST · 174 trials list this drug (36 active)	—	—	Gastrointestinal Stromal Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT04971226Phase 3 · active not recruiting A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP · 174 trials list this drug (36 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT04838041Phase 2 · recruiting Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation · 174 trials list this drug (36 active)	—	—	Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive	1	Observed	clinicaltrials	graph →
→ studied in	NCT03906292Phase 2 · active not recruiting Frontline Asciminib Combination in Chronic Phase CML · 174 trials list this drug (36 active)	—	—	Chronic Myeloid Leukemia, BCR-ABL1 Positive	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths